| Category | Key points | Best supporting citations (pqac IDs) | Key references with year + DOI URL |
|---|---|---|---|
| Identity/Family | Human **ENPP5** corresponds to UniProt **Q9UJA9**, an ectonucleotide pyrophosphatase/phosphodiesterase family member (NPP5), and is described as among the **least characterized ENPP family members**. Comparative family reviews place ENPP5 within the extracellular nucleotide-metabolizing ENPP clade and distinguish it from better-characterized ENPP1/2/3/6/7. | (pqac-00000002, pqac-00000017, pqac-00000018) | Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 ; Borza et al., 2022, J Biol Chem. https://doi.org/10.1016/j.jbc.2021.101526 |
| Topology & localization | ENPP5 is a **type I transmembrane ectoenzyme** with an **N-terminal signal peptide** and a **C-terminal transmembrane helix plus short cytoplasmic tail**; soluble crystallographic constructs used residues **25–430** after removing the membrane/cytoplasmic region. Reviews and primary structural work describe it as **extracellular/membrane-anchored**. | (pqac-00000002, pqac-00000003, pqac-00000008, pqac-00000016, pqac-00000020) | Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 ; Randriamihaja, 2017 structural thesis/article (journal unavailable in retrieved record) |
| Catalytic mechanism/cofactors | ENPP5 has the ENPP alkaline-phosphatase-like catalytic core with the usual **binuclear Zn2+ catalytic center** and a reported **third ENPP5-specific Zn2+ (Zn3)** near the active site. Zn3 is coordinated by **Glu159** and **Asp192** and can contact ribose **2'/3' oxygens**; mutation **E159S** reportedly did **not** change ADP or NAD hydrolysis rates, so Zn3 may aid recognition rather than being essential for catalysis. Catalytic nucleophile is **Thr72/Thr75 numbering depending on construct/species context**. | (pqac-00000003, pqac-00000008, pqac-00000017, pqac-00000021) | Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 ; Borza et al., 2022, J Biol Chem. https://doi.org/10.1016/j.jbc.2021.101526 |
| Substrate specificity & kinetics | Wild-type ENPP5 shows **minimal/undetectable activity** toward many standard ENPP substrates and common nucleotides including **ATP, ADP, UTP**, and is also reported inactive on **p-nitrophenyl-TMP**, **lysophosphatidylcholine**, and **glycerophosphocholine**. In contrast, wild-type ENPP5 hydrolyzes **NAD+** (highest activity among tested substrates) and also cleaves **ADP-ribose (ADPR)** and **UDP-glucose (UDPG)**. Reported **KM for NAD+ is >1 mM** and catalytic efficiency for NAD+ is **0.00067 s−1 μM−1**, indicating very low efficiency. | (pqac-00000003, pqac-00000008, pqac-00000015, pqac-00000017) | Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 ; Borza et al., 2022, J Biol Chem. https://doi.org/10.1016/j.jbc.2021.101526 |
| Key residues/structure | A distinctive **Tyr73** occupies the nucleotide-binding slot where other ENPPs commonly have **Phe**. Structural/functional studies indicate Tyr73 sterically restricts nucleotide binding/hydrolysis; **Y73F** restores activity toward **ATP/ADP/UDP** and broader NTP/NDP hydrolysis. ENPP5 structures reported for human/mouse include **PDB 5VEM, 5VEN, 5VEO**. Mutation of catalytic **Thr75 to Ala** caused precipitation/failure to crystallize, suggesting an important role in **folding/stability**. | (pqac-00000002, pqac-00000003, pqac-00000004, pqac-00000008, pqac-00000019, pqac-00000021) | Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 ; Borza et al., 2022, J Biol Chem. https://doi.org/10.1016/j.jbc.2021.101526 |
| Pathway context | ENPP5 is discussed in the context of **extracellular nucleotide metabolism/purinergic signaling**. Because it can cleave **NAD+**, reviews propose a possible role in **NAD-based neurotransmission**, but this remains **hypothetical** and unvalidated; one structural study also notes possible roles in **neural communication** and purinergic pathways. | (pqac-00000018, pqac-00000019, pqac-00000002) | Borza et al., 2022, J Biol Chem. https://doi.org/10.1016/j.jbc.2021.101526 ; Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 |
| Disease/phenotype associations | Direct causal disease biology for ENPP5 is **weakly established** in the retrieved evidence. Open Targets lists low-confidence associations to **infectious disease, neurodegenerative disease, ptosis, color vision disorder, and severe acute respiratory syndrome**, each supported by only **3 evidence items** in the retrieved context, so these should be treated as **hypothesis-generating rather than confirmed**. In plasma proteomics of frailty, ENPP5 was **negatively associated** with frailty with **estimate −0.0713, SE 0.0102, p = 6.83E−12**. | (pqac-00000000, pqac-00000009) | Open Targets context (retrieved association summary) ; Sathyan et al., 2020, Aging Cell. https://doi.org/10.1111/acel.13193 |
| Recent 2023-2024 findings | Recent literature remains mostly **indirect/omics/review-level** rather than mechanistic. A 2024 review on skin aging/wound healing states ENPP5 was reported as a **key factor in senescence in dermal fibroblasts**, and **knockdown retarded senescence**. A 2024 obesity/mouse study states ENPP5 was **downregulated** after PKCδ inhibitor treatment and refers to ENPP5 as a biomarker related to **insulin resistance**. A 2024 long-COVID preprint identifies ENPP5 among proteins **negatively correlated** with symptom-associated signatures. A 2024 in silico ADC-target study lists **ENPP5 as a potential ADC target**, but without experimental validation in the retrieved excerpt. | (pqac-00000010, pqac-00000013, pqac-00000011, pqac-00000014) | O’Reilly et al., 2024, Front Immunol. https://doi.org/10.3389/fimmu.2024.1429716 ; Osborne et al., 2024, Biology. https://doi.org/10.3390/biology13110943 ; Buggert et al., 2024 preprint. https://doi.org/10.21203/rs.3.rs-4466781/v1 ; Kathad et al., 2024, PLOS ONE. https://doi.org/10.1371/journal.pone.0308604 |
| Applications/implementations | Current real-world use is mainly as a **measurable protein/analyte** rather than a validated therapeutic target. ENPP5 appears in **plasma proteomic biomarker panels** (frailty; long COVID), and **antibodies recognizing ENPP5 in native conformation** have been generated for monitoring cell-surface expression in research settings. Structural data and restored activity in **Y73F** suggest possible utility for **enzyme engineering/substrate-discovery** studies. | (pqac-00000009, pqac-00000011, pqac-00000002) | Sathyan et al., 2020, Aging Cell. https://doi.org/10.1111/acel.13193 ; Möller et al., 2007, Purinergic Signalling. https://doi.org/10.1007/s11302-007-9084-9 ; Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 |
| Evidence gaps | Major gaps remain: **physiological substrate(s)** are still uncertain; activity is only convincingly shown for a narrow set of substrates with **very low NAD+ efficiency**; localization is inferred from topology rather than extensive endogenous cell biology; disease links are largely **correlative**; and proposed roles in **NAD neurotransmission**, **senescence**, and **metabolic disease** lack strong genetic/biochemical validation in the retrieved evidence. Reviews explicitly note that ENPP5 is among the **least characterized** family members and that validation in **KO models** is needed. | (pqac-00000017, pqac-00000018, pqac-00000015, pqac-00000016) | Borza et al., 2022, J Biol Chem. https://doi.org/10.1016/j.jbc.2021.101526 ; Gorelik et al., 2017, FEBS J. https://doi.org/10.1111/febs.14266 ; Randriamihaja, 2017 structural thesis/article (journal unavailable in retrieved record) |


*Table: This table consolidates the strongest retrieved evidence on human ENPP5/Q9UJA9, covering identity, localization, catalytic properties, structure, pathway context, disease links, and recent 2023-2024 findings. It is useful as a compact evidence map showing what is established versus what remains uncertain for functional annotation.*